Overview

Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innoviva’s portfolio includes the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Royalties Earned

Royalties Earned 2019

Press Releases

Date Title and Summary
Toggle Summary GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma
  LONDON --(BUSINESS WIRE)--Oct. 2, 2019-- GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration ( FDA ) seeking an additional indication for the use of once-daily, single-inhaler triple
Toggle Summary Innoviva Reports Second Quarter 2019 Financial Results
Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif. --(BUSINESS WIRE)--Jul.
Toggle Summary Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint
LONDON --(BUSINESS WIRE)--May 2, 2019-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol:
Toggle Summary Innoviva Reports First Quarter 2019 Financial Results
Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif.
Presentations & Events
There are currently no events to display.

Copyright West LLC. Minimum 15 minutes delayed.

Contact

Toll-Free
877-202-1097

Innoviva Investor Relations & Media
Sloane and Company
212-446-9500

For business development inquiries,
please contact investor.relations@inva.com.